Regenex Technology: Passage 2 Quality, Pooling and cGMP
cGMP Manufacturing
Current Good Manufacturing Practice (cGMP) is the quality framework that governs pharmaceutical drug production worldwide. At Regenex Asia, we apply this same framework to every cell therapy product we manufacture — not because it's easy or cheap, but because cell therapy products administered to patients should meet the same quality bar as any other pharmaceutical product.
Our cGMP facility in Kuala Lumpur includes ISO-classified clean rooms with continuous environmental monitoring, validated equipment calibrated to documented standards, qualified personnel trained under cGMP protocols, and a quality management system that governs every step from raw material intake to final product release. Every manufacturing run is documented. Every deviation is investigated. Every batch is independently tested before release.
Passage 2 — Why Cell Quality Matters
Each time mesenchymal stem cells are expanded (passaged) in culture, they undergo subtle but measurable changes. By Passage 4 or 5, MSCs show reduced viability, altered surface marker expression, diminished differentiation potential, shortened telomeres and lower paracrine output — all of which reduce their therapeutic value.
Regenex manufactures MSC products exclusively at Passage 2: the earliest commercially viable expansion stage. This means fewer cells per batch and higher production costs — but it also means every patient and clinic partner receives cells at their peak regenerative potential. Our exosome products inherit this advantage, as they are derived from the same Passage 2 MSC cultures.
Pooled Donor Technology
Single-donor MSC batches carry inherent variability — one donor's cells may perform differently from another's due to age, genetics and biological variation. Regenex addresses this through pooled donor technology: combining cells from multiple screened, qualified donors into a single manufacturing batch.
The result is a product with reduced donor-to-donor variability and more consistent quality characteristics across batches. Every donor in the pool undergoes comprehensive infectious disease screening and health assessment before their tissue enters our manufacturing process.
Facility Overview
Our facility includes dedicated areas for cell isolation, expansion, quality testing, cryogenic storage and product release — each operating under controlled environmental conditions. The laboratory is purpose-built for cell therapy manufacturing and is subject to regular inspection by KKM.